2016
DOI: 10.1002/14651858.cd011476.pub2
|View full text |Cite
|
Sign up to set email alerts
|

Liposomal bupivacaine peripheral nerve block for the management of postoperative pain

Abstract: A lack of evidence has prevented an assessment of the efficacy of liposomal bupivacaine administered as a peripheral nerve block. At present there is a lack of data to support or refute the use of liposomal bupivacaine administered as a peripheral nerve block for the management of postoperative pain. Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
20
0

Year Published

2016
2016
2020
2020

Publication Types

Select...
5
2

Relationship

3
4

Authors

Journals

citations
Cited by 40 publications
(21 citation statements)
references
References 30 publications
(2 reference statements)
1
20
0
Order By: Relevance
“…This NMA supports both the efficacy of TAP blocks at 24 h after surgery, and their reduced efficacy in the longer term, demonstrated by a lack of benefit over the systemic opiate group at 48 h. Slow‐release liposomal bupivacaine has been used in an attempt to increase the duration of effect of TAP blocks, and has been shown to be more effective than placebo for postoperative pain. However, whether this strategy is superior to non‐liposomal bupivacaine awaits further research. Unpublished trials in colorectal and gynaecological surgery may shed further light on the effectiveness of liposomal bupivacaine (NCT03638635, NCT02740114).…”
Section: Discussionsupporting
confidence: 58%
“…This NMA supports both the efficacy of TAP blocks at 24 h after surgery, and their reduced efficacy in the longer term, demonstrated by a lack of benefit over the systemic opiate group at 48 h. Slow‐release liposomal bupivacaine has been used in an attempt to increase the duration of effect of TAP blocks, and has been shown to be more effective than placebo for postoperative pain. However, whether this strategy is superior to non‐liposomal bupivacaine awaits further research. Unpublished trials in colorectal and gynaecological surgery may shed further light on the effectiveness of liposomal bupivacaine (NCT03638635, NCT02740114).…”
Section: Discussionsupporting
confidence: 58%
“…Pain is a common postoperative complaint following arthroplasty, particularly of the knee (Hamilton, Athanassoglou et al., ; Hamilton, Strickland et al., ; Szots, Pedersen, Hordam, Thomsen, & Konradsen, ). Pain has also been recognised as a possible cause of confusion and disorientation in the immediate postoperative phase for the elderly (Duggleby & Lander, ).…”
Section: Discussionmentioning
confidence: 99%
“…By using multimodal techniques, ranging from preoperative education to surgical site local anaesthetic wound infiltration, ERPs have been demonstrated to significantly reduce perioperative pain and opiate consumption and are associated with significant cost savings to the healthcare system through a reduced length of stay (LOS) and associated healthcare costs (Hamilton, Strickland, & Pandit, ; Hamilton, Athanassoglou et al., ;, Hamilton et al., ). In addition, the short‐term benefits seen with the use of ERPs have been reported to translate into reduced long‐term patient morbidity and mortality as well as improved functional outcomes (Ibrahim, Twaij, Giebaly, Nizam, & Haddad, ; Nicholson et al., ; Wylde et al., ).…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…This system allows LA deposit in the center of the liposomes, being involved by a double lipid layer. This setting allows a slower, controlled, and gradual release of LA, (72-96 h), consequently providing extended analgesic duration [20][21][22][23]. Liposomal bupivacaine (LB) has a decreased spread when compared with conventional bupivacaine.…”
Section: Liposomal Formulationsmentioning
confidence: 99%